S. Chaudhari

Superficial ocular malignancies treated with strontium-90 brachytherapy: long term outcomes

Purpose The incidence of conjunctival malignancies is less than 1%. Though surgical excision remains the mainstay of treatment, the incidence of positive surgical margins and local recurrence rates are high, which is approximately up to 33% in negative margins and 56% in positive margins. Radiotherapy reduces the risk of recurrence in these cases. Brachytherapy using β emitters such as strontium-90 (90Sr) is an ideal treatment technique for these tumors with the advantage of treating only a few millimeters of tissue while sparing the underlying normal eye. We report the long term outcomes in the form of local control and late sequelae of patients with conjunctival malignancies treated with 90Sr applicator brachytherapy. Material and methods During 1999-2013, 13 patients with conjunctival tumors, treated using 90Sr brachytherapy were analyzed. Brachytherapy was either in a post-operative adjuvant or in a recurrent setting. Local control (LC), disease free survival (DFS), overall survival (OS), and late sequelae were evaluated. Results The median age at presentation was 47 years (range: 11-71 years). Thirteen patients with 15 tumors were treated. The commonest histology was squamous cell carcinoma. The median dose was 44 Gy over 11 fractions. The median follow up of all the patients was 51 months (range: 3-139 months). The median follow up of patients with carcinoma only was 64 months with a LC and DFS of 90.9% at 5 years. None of the patients developed ≥ grade II Radiation Therapy Oncology Group (RTOG) acute toxicities. One patient developed a focal scar and another developed corneal opacification at the limbus. Vision was not impaired in any of the patients. Conclusions Strontium-90 brachytherapy used in early invasive conjunctival malignancies as an adjunct to surgery in primary and recurrent settings, results in optimal disease control and ocular functional outcomes.

Adaptive radiation therapy for pediatric head and neck malignancies: Dosimetric implications

PURPOSE This study was designed to evaluate the role of adaptive radiation therapy for children receiving curative radiation therapy to the head and neck region. METHODS AND MATERIALS Ten children receiving definitive, conformal radiation therapy to the head and neck region were prospectively evaluated for anatomic changes during the course of radiation therapy. Images were acquired midway through the number of planned radiation therapy fractions during the planned course of radiation therapy. Body contours, target volumes, and organs at risk were redrawn on the new set of images. Two sets of additional treatment plans were generated: (1) a nonoptimized plan (plan 2), that is, an overlay of the original plan (plan 1) on the new set of contours, and (2) an optimized plan (plan 3) with the new set of contours. These 3 sets of plans were then compared for dosimetric differences. RESULTS Five children had nasopharynx carcinoma, whereas the other 5 had embryonal rhabdomyosarcoma. The average reduction in gross tumor volume was 40% (mean volume, 41.87 mL; P = .005). The average changes in right and left parotid volumes were 2.72 and 1.92 mL, respectively. With nonoptimized plans, the average increase in maximum dose to the spinal cord was 15% (79.99%-94.99%; P = .013). With reoptimization, the maximum dose to the spinal cord decreased from 94.99% to 85.26% (mean difference, -9.73%; P = .02). Average D99 for the planning target volume (dose received by 99% of the target volume) was 88.66% and 86.89% with the original and reoptimized plans, respectively (P = .50). For the entire group, the mean conformation number index with nonoptimized plans was reduced from 0.734 to 0.628 (P = .013). This improved with reoptimization (P = .114). The homogeneity index improved with reoptimization from a mean value of 0.113 to 0.098 (P = 0.28). For nonoptimized plans, the average integral dose increased from 74.66 to 76.27 L-Gy (P = .486) compared with the original plans. Reoptimization resulted in a 5% average reduction in the integral dose, from 76.27 to 72.28 L-Gy (P = .007). CONCLUSIONS This study demonstrates the usefulness of adaptive radiation therapy for children receiving radiation therapy to the head and neck region.

Volume changes with stereotactic body radiation therapy in early lung cancer: Time trends and outcomes

Tumour response during stereotactic body radiotherapy (SBRT) could be heterogeneous and the pattern of response may be used as an early predictor for outcome.

Eye lens dose estimation during interventional radiology and its impact on the existing radiation protection and safety program: In the context with new International Commission on Radiological Protection guidelines

Interventional radiology procedures are used for diagnosing certain medical conditions. The radiologists and medical professionals are exposed to ionizing radiation from X-rays of the equipments and also from scattered radiation during these procedures. The radiation exposure to the eye is more important to be assessed while performing such procedures. ICRP has revised the annual dose limit to the lens of the eye from 150 mSv to 20 mSv. In view of this revision, a study was carried out to evaluate the dose to the lens of the eye during interventional radiology. The paper gives the details of calibration of TLDs using a head phantom, predict annual equivalent dose and also highlight the dependence of dose on the position of TLD on the head. It is observed the predicted annual equivalent doses to the lens of eye are in the range of 25 mGy to 37 mGy. The selection of dosimeter placement may also result in an uncertainty of -14% to 20%.

Dosimetric validation of new semiconductor diode dosimetry system for intensity modulated radiotherapy

INTRODUCTION The new diode Isorad was validated for intensity modulated radiotherapy (IMRT) and the observations during the validation are reported. MATERIALS AND METHODS The validation includes intrinsic precision, post-irradiation stability, dose linearity, dose-rate effect, angular response, source to surface (SSD) dependence, field size dependence, and dose calibration. RESULTS The intrinsic precision of the diode was more than 1% (1 σ). The linearity found in the whole range of dose analyzed was 1.93% (R² = 1). The minimum and maximum variation in the measured and calculated dose were found to be 0.78% (with 25 MU at ioscentre) and 4.8% (with 1000 MU at isocentre), respectively. The maximal variation in angular response with respect to arbitrary angle 0° found was 1.31%. The diode exhibited a 51.7% and 35% decrease in the response in the 35 cm and 20 cm SSD range, respectively. The minimum and the maximum variation in the measured dose from the diode and calculated dose were 0.82% (5 cm × 5 cm) and 3.75% (30 cm × 30 cm), respectively. At couch 270°, the response of the diode was found to vary maximum by 1.4% with ± 60 gantry angle. Mean variation between measured dose with diode and planned dose by TPS was found to be 1.3% (SD 0.75) for IMRT patient-specific quality assurance. CONCLUSION For the evaluation of IMRT, use of cylindrical diode is strongly recommended.